12 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has declined 5.2% per year over the past 5 years.
Operating margin has contracted, at -28.2% in the latest year.
Financial health
Operating income covered interest expense -1214.6× in the latest year.
The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$323M
-$61M
40.6%
-28.2%
-5.4%
-5.0%
-$124M
—
$50M
2024
$283M
-$43M
37.8%
-26.1%
-3.8%
-3.5%
-$19M
—
$55M
2023
$289M
-$168M
36.1%
-67.6%
-14.8%
-13.6%
$5M
—
$97M
2022
$619M
$143M
59.3%
28.8%
11.3%
10.3%
$235M
—
$80M
2021
$993M
$507M
78.3%
68.1%
43.8%
39.7%
$515M
—
$165M
2020
$422M
$214M
78.7%
68.8%
37.6%
30.6%
$105M
—
$87M
2019
$33M
-$411000
56.6%
-1.3%
-0.5%
-0.5%
$4M
—
$12M
2018
$21M
-$6M
49.9%
-23.7%
-11.0%
-10.4%
-$3M
—
$7M
2017
$19M
-$3M
54.3%
-18.6%
-4.6%
-4.4%
-$2M
—
$6M
2016
—
-$5M
—
—
-9.8%
-9.2%
$617000
—
$8M
2015
—
-$8M
—
—
-161.6%
-142.6%
-$3M
—
$489000
2014
—
-$4M
—
—
-254.3%
—
-$5M
—
—
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Jun '26
$85M
-$30M
30.1%
-42.2%
-2.9%
-2.7%
-$28M
—
$26M
Mar '26
$71M
-$25M
30.2%
-48.7%
-2.4%
-2.1%
$2M
—
$23M
Dec '25
$83M
-$23M
39.1%
-43.5%
-2.1%
-1.9%
-$83M
—
$50M
Sep '25
$84M
-$7M
42.2%
-18.3%
-0.6%
-0.5%
$5M
—
$118M
Jun '25
$82M
-$19M
42.1%
-24.1%
-1.7%
-1.6%
-$37M
—
$88M
Mar '25
$73M
-$12M
38.6%
-26.9%
-1.0%
-1.0%
-$9M
—
$67M
Dec '24
$76M
-$6M
41.8%
-21.2%
-0.5%
-0.5%
$21M
—
$55M
Sep '24
$72M
-$15M
37.3%
-23.8%
-1.3%
-1.2%
-$35M
—
$58M
Jun '24
$71M
-$9M
37.3%
-26.6%
-0.8%
-0.7%
-$9M
—
$65M
Mar '24
$64M
-$13M
34.3%
-33.8%
-1.2%
-1.1%
$3M
—
$55M
Dec '23
$71M
-$128M
35.8%
-214.3%
-11.3%
-10.4%
$12M
—
$97M
Sep '23
$85M
-$13M
47.0%
0.3%
-1.0%
-1.0%
$5M
—
$84M
Jun '23
$68M
-$11M
30.3%
-29.2%
-0.9%
-0.8%
-$2M
—
$58M
Mar '23
$66M
-$15M
28.4%
-37.5%
-1.2%
-1.1%
-$10M
—
$66M
Dec '22
$68M
-$24M
19.2%
-54.0%
-1.9%
-1.7%
$28M
—
$80M
Sep '22
$106M
$2M
43.6%
0.3%
0.1%
0.1%
$15M
—
$169M
Jun '22
$125M
$12M
52.1%
10.2%
0.9%
0.8%
$8M
—
$139M
Mar '22
$320M
$154M
75.7%
63.1%
11.8%
10.5%
$183M
—
$353M
Dec '21
$252M
$104M
75.3%
59.9%
9.0%
8.2%
$71M
—
$165M
Sep '21
$228M
$123M
80.9%
69.9%
11.8%
10.2%
$149M
—
$215M
Valuation over time
How the market has priced FLGT against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 6.0× (Mar '23) to 5.5× (Dec '23).
The price-to-sales ratio has risen from 1.4× (Mar '23) to 1.7× (Sep '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is FLGT growing its revenue and profit?
Over the past 5 years, Fulgent Genetics, Inc.'s revenue has declined 5.2% per year. These are computed facts, not advice.
How much debt does FLGT have?
As of FY2025, Fulgent Genetics, Inc. reported — of total debt against $50M of cash; operating income covered interest expense -1214.6×.
What is FLGT's profit margin?
In FY2025, gross margin was 40.6%, operating margin -28.2%, and net margin -18.8%.
What is FLGT's P/E ratio?
As of Sep '26, Fulgent Genetics, Inc. traded at a price-to-earnings ratio of about 5.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.